cardiovascular gene therapy
Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies
Rocket Pharmaceuticals; layoffs; restructuring; 30% workforce reduction; cardiovascular gene therapy; adeno-associated virus (AAV); Danon disease; PKP2-associated cardiomyopathy; BAG3-associated dilated cardiomyopathy; operating cost reduction; Fanconi Anemia; Pyruvate Kinase Deficiency; KRESLADI
XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy
XyloCor Therapeutics, Series B funding, cardiovascular gene therapy, XC001, refractory angina, CABG, clinical trials